文献速递产科母胎医学

微滴数字PCR是分析孕妇血浆中长片段游离DNA的经济有效方法:在子痫前期中的应用

Droplet digital PCR is a cost-effective method for analyzing long cell-free DNA in maternal plasma: Application in preeclampsia.
PubMed 文献 · Prenat Diagn · 2023-09-01

本研究用微滴数字PCR(ddPCR)分析10例子痫前期与16例正常妊娠孕妇血浆中长片段游离DNA(cfDNA)的百分比。LINE-1 170 bp检测显示子痫前期组长cfDNA中位百分比显著低于正常对照组(28.9% vs 35.1%,p < 0.0001),VCP 533 bp检测亦显示显著降低(6.6% vs 8.7%,p = 0.014),LINE-1检测的鉴别能力优于VCP 533 bp检测(ROC曲线下面积0.94 vs 0.79)。作者认为ddPCR是解锁血浆长cfDNA诊断信息的经济有效方法,可能用于子痫前期检测,但需进一步开展更大队列的纵向研究评估其临床效用。

要点

  • 子痫前期组LINE-1 170 bp长cfDNA中位百分比为28.9%,低于正常对照组的35.1%(p < 0.0001)。
  • 子痫前期组VCP 533 bp长cfDNA中位百分比为6.6%,低于正常对照组的8.7%(p = 0.014)。
  • LINE-1检测鉴别子痫前期与正常妊娠的ROC曲线下面积为0.94,优于VCP 533 bp检测的0.79。

核心结论

  • ddPCR是解锁血浆长cfDNA诊断信息的经济有效方法,可能用于子痫前期的检测。
  • 需进一步开展更大队列的纵向研究评估该检测的临床效用。

研究设计与样本

  • 研究分析10例子痫前期孕妇与16例正常妊娠孕妇的血浆样本。
  • 采用两种靶向单拷贝基因VCP的ddPCR检测和一种靶向LINE-1重复区域的ddPCR检测,分别测量长于533 bp、1001 bp和170 bp的长cfDNA百分比。
  • LINE-1检测依据计算机模拟PCR分析指导开发,以更好地区分子痫前期与正常妊娠。

主要发现

  • LINE-1 170 bp检测显示子痫前期组长cfDNA中位百分比为28.9%,正常对照组为35.1%(p < 0.0001)。
  • VCP 533 bp检测显示子痫前期组长cfDNA中位百分比为6.6%,正常对照组为8.7%(p = 0.014)。
  • LINE-1检测的鉴别能力优于VCP 533 bp检测(ROC曲线下面积0.94 vs 0.79)。

关键数值与推荐

  • 子痫前期组LINE-1 170 bp长cfDNA中位百分比28.9% vs 正常对照组35.1%(p < 0.0001)。
  • 子痫前期组VCP 533 bp长cfDNA中位百分比6.6% vs 正常对照组8.7%(p = 0.014)。
  • LINE-1检测ROC曲线下面积0.94,VCP 533 bp检测ROC曲线下面积0.79。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 需进一步开展更大队列的纵向研究评估该检测的临床效用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Long cell-free DNA (cfDNA) can be found in the plasma of pregnant women and cancer patients. We investigated if droplet digital PCR (ddPCR) can analyze such molecules for diagnostic purposes using preeclampsia as a model. METHOD: Plasma samples from ten preeclamptic and sixteen normal pregnancies were analyzed. Two ddPCR assays targeting a single-copy gene, VCP, and one ddPCR assay targeting LINE-1 repetitive regions were used to measure the percentages of long cfDNA >533, 1001, and 170 bp, respectively. The LINE-1 assay was developed as guided by in silico PCR analyses to better differentiate preeclamptic and normal pregnancies. RESULTS: Preeclamptic patients had a significantly lower median percentage of long cfDNA than healthy pregnant controls, as determined by the LINE-1 170 bp assay (28.9% vs. 35.1%, p < 0.0001) and the VCP 533 bp assay (6.6% vs. 8.7%, p = 0.014). The LINE-1 assay provided a better differentiation than the VCP 533 bp assay (area under ROC curves, 0.94 vs. 0.79). CONCLUSION: ddPCR is a cost-effective approach for unlocking diagnostic information carried by long cfDNA in plasma and may have applications for the detection of preeclampsia. Further longitudinal studies with larger cohorts are required to assess the clinical utility of this test.

来源:Prenat Diagn,查看原文。版权归原作者所有。

引用

  1. Gai W, Yu SCY, Chan WTC, et al. Droplet digital PCR is a cost-effective method for analyzing long cell-free DNA in maternal plasma: Application in preeclampsia. Prenat Diagn. 2023. PMID: 37655424. doi:10.1002/pd.6432

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。